+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study



Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study



Bmc Cardiovascular Disorders 17(1): 166



The benefit of statin on the management of Type 2 Diabetes Mellitus (T2DM) among Chinese patients in primary care is not clear nor fully implemented in clinical practice. This study aimed to evaluate and quantify the benefit of statin on the overall cardiovascular risk and all-cause mortality in patients with T2DM. Uncomplicated diabetic patients with baseline low-density-lipoprotein cholesterol (LDL-C) > 2.6 mmol/L and without statin use before baseline in 2010 were followed-up for 5 years for cardiovascular disease (CVD) events and all-cause mortality. Propensity score matching analysis was conducted to identify patients who were newly prescribed statin at baseline and then compared to non-statin users with similar baseline characteristics. Subgroup analysis was done within the statin group to detect any difference in outcomes between patients achieving target LDL-C of <2.6 mmol/L and not. Multivariable Cox proportional hazards regression with adjustment of all baseline covariates was used to evaluate the effect of statin on outcome events. Hazard ratio (HR) and its 95% confidence intervals were reported. 10,104 pairs of diabetic patients were propensity score matched. Statin users had an extra drop of 1.21 mmol/L in LDL-C than non-users. Statin group had a CVD incidence rate of 16.533 per 1000 person-years whereas comparison group had 32.387 per 1000 person-years (HR: 0.458) during a median follow-up period of 50.5 months. Statin group had a mortality rate of 8.138 deaths per 1000 person-years whereas comparison group had 19.603 deaths per 1000 person-years (HR: 0.378). For patients prescribed with statin, the HR was 0.491 for CVD and 0.487 for all-cause mortality if target of LDL-C < 2.6 mmol/L achieved compare to those not achieved. Use of statin was associated with a significant decrease in CVD risk and all-cause mortality among diabetic patients in primary care, and the risk reduction was most significant if the target of LDL-C less than 2.6 mmol/L was achieved.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060276933

Download citation: RISBibTeXText

PMID: 28645252

DOI: 10.1186/s12872-017-0599-x


Related references

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation 138(15): 1605-1607, 2018

Liraglutide Reduces Cardiovascular Events And Mortality In Type 2 Diabetes Independent Of Ldl Cholesterol And Statin Use: Results Of The Leader Trial. Canadian Journal of Cardiology 34(10): S123-S124, 2018

Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovascular Diabetology 14: 137, 2016

Prediction of five-year all-cause mortality in Chinese patients with type 2 diabetes mellitus - A population-based retrospective cohort study. Journal of Diabetes and Its Complications 31(6): 939-944, 2017

A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences 23(5): 2302-2310, 2019

Association of variability in hemoglobin A1c with cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus - A retrospective population-based cohort study. Journal of Diabetes and Its Complications 30(7): 1240-1247, 2018

Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clinical Cardiology 35(12): 722-729, 2013

Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovascular Diabetology 14: 38, 2016

Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study. Bmc Nephrology 18(1): 47, 2017

Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American Journal of Kidney Diseases 54(5): 902-911, 2009

Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy. Journal of the American College of Cardiology 43(5 Suppl. A): 504A, March 3, 2004

Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Safety 32(8): 675-690, 2009

Mortality risks of type 2 diabetes mellitus among elderly patients: a 17-year cohort study. Zhonghua Yi Xue Za Zhi 94(33): 2597-2601, 2015

Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study. Cardiovascular Diabetology 12: 126, 2014

Predictive value of ankle-brachial index and blood glucose on the outcomes of six-year all-cause mortality and cardiovascular mortality in a Chinese population of type 2 diabetes patients. International Angiology 31(6): 586-594, 2013